Diesel Exhaust Particulates and Allergy Sensitization Along Commute Routes

Diesel exhaust particulates can do more than irritate a commuter’s airways. They can amplify the immune response to pollen, dust mites and other ordinary allergens, making traffic exposure a contributor to allergies. Understanding that link calls for finding which allergens are involved and, where appropriate, treating the immune system’s learned overreaction as well as easing symptoms.

Why DEPs are more than an irritant: the adjuvant mechanism explained

During pollen season, a bus passenger beside an open window can breathe allergens and diesel exhaust together. A cyclist on a diesel-heavy street encounters the same combination. It is tempting to think of these as separate burdens, with pollen causing allergy and exhaust causing irritation. But diesel exhaust particulates, or DEPs, can change how the immune system responds to the pollen itself.

DEPs are constituents of fine particulate matter known as PM₂.₅. Experimental evidence across multiple models shows that they can act as immune adjuvants. Here, they push the immune system toward allergy mode, increasing allergy-associated antibodies and inflammatory signals (IgE amplification and Th2 skewing). The word adjuvant describes this amplifying role, rather than making a claim that the particles are harmless on their own.

This distinction changes the question that matters along a commute route. The amount of pollen or dust is only part of the exposure picture. If DEPs help prime the immune system to overreact to an allergen it might otherwise tolerate, the surrounding traffic air also matters. Allergen burden alone cannot explain the full sensitization risk.

What the synergy between DEPs and allergens produces in the human airway

Human exposure studies show what this amplification looks like inside the airway. Diaz-Sanchez and colleagues found that nasal challenge with DEP plus allergen produced larger ragweed-specific antibody responses, including IgE and IgG₄, than DEP alone. The combination also shifted immune signals toward allergic sensitization.

Hosseini et al. at the University of British Columbia took the investigation into the lung. They recruited allergen-sensitized volunteers, exposed them to diesel exhaust and then introduced allergen into the lung. Samples taken from the bronchial lining showed greater activation of mast cells and eosinophils under combined exposure than under filtered air plus allergen. These are cells involved in allergic inflammation, so their activation gives the comparison biological weight.

The study, registered as NCT01792232 on ClinicalTrials.gov, provided novel direct evidence of the interaction in human lung tissue. It does not establish that every exposed commuter will develop an allergy, particularly because the volunteers were already sensitized. It does show that diesel exhaust can intensify the airway’s response to allergen beyond the response to allergen alone.

NO₂ as a second adjuvant: why particle filters on diesel vehicles don't solve the problem

The obvious response to a particle problem is to remove the particles. A high-efficiency filter achieving 93% particle reduction did not prevent enhanced bronchial hyperresponsiveness after diesel exhaust and allergen challenge. In other words, the airways still became more reactive despite a substantial fall in particles.

That finding points to the gas phase of exhaust, particularly nitrogen dioxide, or NO₂. NO₂ can act as an adjuvant in its own right, so both NO₂ and DEPs can promote sensitization. Removing one component leaves another route through which exhaust can enhance the response to allergens.

For commuters, visibly smoky conditions are therefore not the only concern. A bus corridor can still expose passengers and pedestrians to gas-phase exhaust and ambient allergens when particle emissions are lower. The reasonable policy inference is narrower than saying particle filters are useless. It is that particle reduction alone should not be treated as proof that the allergy-related effects of diesel exhaust have been solved.

What repeated DEP exposure does beyond sensitization: the hypersensitivity pneumonitis pathway

Repeated exposure raises a further question about whether the immune changes stop at ordinary allergy. Lee et al., published in Environmental Research on 15 September 2026, investigated that question in mice. Repeated DEP exposure produced poorly formed non-caseating granulomatous lung inflammation, a hallmark diagnostic feature of hypersensitivity pneumonitis, or HP. This points toward a separate form of lung disease driven by the immune system, with a pathway that differs from hay fever.

The study’s tests of gene activity and proteins also showed changes in how immune cells process and present the material they meet. They found enhanced immune complex-related engulfment through Fcγ receptors (Fcγ receptor-mediated phagocytosis). These mechanisms involve Type III and Type IV hypersensitivity as well as the Type I, IgE-mediated pathway linked to classical allergy. The mouse lungs also had patterns of gene activity in common with human HP lungs in the pathways that control the immune response and tissue remodeling.

These findings show that repeated exposure can produce a broader pattern of immune injury in an animal model, with features relevant to human disease. That matters because HP can progress from non-fibrotic to fibrotic forms. The science is tracking a possible chain from exposure to lung remodeling, strengthening the case for taking persistent exposure and symptoms seriously without treating an animal result as a human diagnosis.

Who is actually exposed: commuters, children near roads, and the geography of DEP risk

Bernstein's CCAAPS birth cohort study recruited 762 infants born to atopic parents, comparing those living close to a major road with those living farther away. Higher elemental carbon attributable to traffic, used as a proxy for diesel exhaust, was significantly associated with wheezing at age one and persistent wheezing at age three. Proximity to stop-and-go traffic with high concentrations of buses and trucks also predicted persistent wheezing during infancy.

These are findings about children. But adults who use the same roads are exposed in the same places. The California Air Resources Board identifies freight and goods movement, transit and on-road vehicles as key diesel exposure categories. A bus rider at a window, a cyclist beside a freight corridor and someone walking the last block from a transit stop can all encounter exhaust mixed with local allergens.

The relevant allergens also extend beyond roadside pollen. Sensitization to indoor allergens such as dust mites typically precedes sensitization to outdoor pollens, and DEPs can amplify responses to whichever allergens are locally dominant. Staying indoors before or after travel does not erase established dust mite sensitization. Congestion and recurring sneezing become the daily baseline, leaving no obvious contrast that prompts someone to question the route.

How untreated DEP-amplified allergies compound into sleep disruption and cognitive impairment

When allergic inflammation becomes part of daily life, it can affect people even after their travel has ended. Nasal congestion is often worse when lying flat. That obstruction encourages mouth breathing during sleep, which can contribute to snoring and sleep-disordered breathing, including sleep apnea. The chain begins with an immune response in the airway but can end in sleep that no longer restores alertness.

These findings do not show that diesel exposure is the direct cause of every bout of fatigue or brain fog. When congestion repeatedly disrupts sleep, the resulting deficit can compound problems with cognitive performance. The burden is then more than sneezing on the bus or reaching for tissues at work.

The gradual nature of this change makes it particularly easy to normalize. A commuter may remember no clear point when sleep worsened, only a growing expectation of feeling tired. That lack of a memorable onset can obscure the link to an established allergy problem. Treating the underlying sensitization offers a way to ease this chain of effects driven by allergy. It makes untreated allergy an important part of the picture.

Why symptom medications can't address what DEPs have done to the immune system

Symptom medicines have a legitimate role, but they work at a different point in the process. Oral antihistamines, including loratadine, fexofenadine and cetirizine, can temporarily suppress symptoms. They do not reverse the allergy-directed immune signaling or IgE amplification associated with DEP co-exposure.

Nasal corticosteroid sprays reduce inflammation, but they are not disease-modifying either. Their common side effects include nosebleeds and nasal dryness. Antihistamine nasal sprays have a different side-effect profile, including bitter taste, drowsiness, headache, nosebleeds and nasal burning or stinging. These limits do not make treatment to ease symptoms harmful in itself or remove the need for it.

Drug safety distinctions also matter. The FDA added a boxed warning to montelukast/Singulair, a leukotriene receptor antagonist, for concerns including depression and suicidal thinking. Its warning should not be carried over to antihistamines. A medicine can ease the response after it starts without teaching the immune system to tolerate the allergen that set it off.

How sublingual immunotherapy addresses the immune rebalancing that DEP-sensitized commuters actually need

Sublingual immunotherapy, or SLIT, aims at that learned response. Allergen placed under the tongue is taken up by cells in the mouth’s lining that favor immune tolerance (tolerogenic dendritic cells). These cells process the allergen in a way that promotes regulation. In that sense, its intended immune effect runs in the opposite direction to DEP adjuvancy.

SLIT shifts allergy-directed signaling toward a more regulated response (Th2 toward Th1, with regulatory T-cell modulation). It lowers signals that play a part in allergic inflammation, including IL-4, IL-5 and IL-13. That dampens downstream activation of mast cells, basophils and eosinophils. The target is tolerance to a particular allergen.

The practical fit matters for people whose travel already consumes much of the day. SLIT drops can be administered at home after an initial visit, removing the weekly clinic commitment associated with allergy shots. Severe systemic reactions are rare, and no fatalities have been reported with SLIT, though that does not mean it is risk-free. Subcutaneous immunotherapy requires in-office observation after injections because of anaphylaxis risk. FDA-approved SLIT forms are tablets for specific allergens, including ragweed, certain grasses and dust mites, so drops and approved tablets should not be treated as interchangeable regulatory categories.

Getting tested when you suspect your commute is driving your symptoms

Testing helps link a person's likely exposure to treatment for the allergens involved. A specific IgE blood test can identify sensitization, and home finger-prick sampling offers a practical entry point for commuters. Skin-prick testing is an in-clinic alternative. For suspected mold allergy, a blood sample sent to a medical laboratory can be tested for sensitivity to specific mold types. The purpose is to move beyond a general suspicion of traffic-related symptoms to a clearer picture of the immune response.

That picture needs physician-guided interpretation. Geography and degree of urbanization affect which airborne allergens are relevant, so a generic panel may not answer the right question. Indoor and outdoor sensitization can also overlap, with dust mite sensitization preceding pollen sensitivity. A single-allergen test can miss that layered pattern. An ambiguous result therefore needs interpretation in the context of symptoms and exposure.

Allergen testing identifies sensitization while leaving its attribution to a particular commute unproven. Even with that limitation, it can guide a treatment plan aimed at what the immune system now reacts to. Early identification can allow appropriate immunotherapy to begin before sensitization broadens further across allergen classes.